EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 is a drug used in the measurement of oxygen in tumor tissue. PURPOSE: Phase II trial to study the effectiveness of EF5 in assessing tumor response to anticancer therapy in patients who have stage I, stage II, or stage III non-small cell lung cancer.
Checked against the public recordLast updated May 1, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Duke University
- Interventions being studied
- Drug: EF5; Other: flow cytometry; Other: immunohistochemistry staining method
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed or suspected non-small cell lung cancer (NSCLC) * If there is no histological or cytological documentation of NSCLC, must have at least a 75% probability of having NSCLC * Clinical or pathological stage I-III * Patients in whom pre-surgical staging has not definitively established stage IV disease are allowed * Tumor mass of ≥ 1.5 cm in maximum diameter must be present on CT scan and must be included in the planned surgical biopsy or resection * Must be planning to undergo a surgical staging or treatment procedure (including mediastinoscopy, wedge resection, lobectomy, or pneumonectomy) PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * 0-2 Life expectancy: * Not specified Hematopoietic: * WBC \> 2,000/mm\^3 * Platelet count \> 100,000/mm\^3 Hepatic: * Bilirubin normal Renal: * Creatinine normal OR * Creatinine clearance ≥ 60 mL/min Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 1 month after study participation * Able to hold breath for 27 seconds * No allergy to IV contrast dye * No history of grade III or IV peripheral neuropathy PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * See Disease Characteristics
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Duke Comprehensive Cancer CenterDurham, North Carolina
- Veterans Affairs Medical Center - DurhamDurham, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 1, 2015. Always confirm current availability with the study team.